Chinese pharmaceutical company Innovent Biologics has entered into a landmark partnership with U.S. pharmaceutical giant Pfizer, signing a deal valued at up to US$10.5 billion to develop and commercialize 12 oncology programs. According to the South China Morning Post, the agreement includes a US$650 million upfront payment from Pfizer to Innovent, with potential milestone payments reaching US$9.85 billion across development, regulatory, and commercial stages, plus double-digit royalties on each approved product.
The portfolio comprises eight early-stage assets originated by Innovent and four discovery programs proposed by Pfizer. Under the terms of the agreement, Innovent will lead Phase 1 clinical trials for all 12 programs, while Pfizer will lead global development. The collaboration is structured to leverage the complementary strengths of both companies across different markets and geographies.
(Related: China’s Biotech Boom Drives Record Drug Approvals and $60 Billion in Global Licensing Deals)
A Complex, Multi-Tier Partnership Structure
The deal’s structure reflects the nuanced realities of the U.S.-China pharmaceutical relationship. Four of the programs will be jointly developed and co-commercialized in the U.S. and Europe, with Innovent retaining rights in China. Another four programs grant Pfizer an exclusive license outside of China, while the remaining four provide Pfizer with an exclusive global license, a tiered approach that allows Innovent to maintain a domestic footprint while giving Pfizer broad international control over the most promising assets.
Michael Yu, Innovent’s chairman and executive director, emphasized the strategic importance of the deal. “The company views this collaboration as another milestone towards achieving global capabilities,” Yu stated. “By leveraging both companies’ complementary resources, [Innovent] can develop its early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide.”
The deal follows Innovent’s US$11.4 billion partnership with Japan’s Takeda Pharmaceutical, announced in October 2025, establishing the Suzhou-based company as one of China’s most globally active biotech firms. Innovent is also notable for being the first Chinese company cleared to sell weight-loss drugs, a market that has attracted enormous global interest following the success of GLP-1 therapies.
China’s Biotech Out-Licensing Boom
The Innovent-Pfizer deal is indicative of a broader and accelerating boom in China’s biotechnology sector. In the first quarter of 2026 alone, China’s cross-border out-licensing deals reached US$60 billion, according to data from the National Medical Products Administration. This follows a record US$135.7 billion in full-year out-licensing totals in 2025, reflecting the rapid maturation of China’s drug discovery capabilities and the growing appetite of global pharmaceutical companies to access Chinese innovation pipelines.
Innovent reported its first full-year profit since its 2018 IPO in 2025, with a net profit of 813.6 million yuan, compared to a loss of 94.63 million yuan in 2024. In the first quarter of 2026, total product revenue exceeded 3.8 billion yuan, up over 50% year on year. Innovent’s shares rose 11.36% to HK$83.35 following the announcement of the Pfizer deal.
(Related: Beijing Mandates 32 Measures to Accelerate AI Drug Discovery and Surgical Robots)
China’s drug regulator has cleared 19 pharmaceuticals so far in 2026, with 15 originating from domestic companies, a ratio that underscores the increasing quality and commercial viability of Chinese pharmaceutical innovation. As China continues to account for a growing share of newly launched clinical trials globally, partnerships like the one between Innovent and Pfizer highlight the deepening integration of Chinese biotech into the global pharmaceutical ecosystem.
The role of artificial intelligence in accelerating Innovent’s pipeline development is worth noting. Chinese biotech companies have been among the most aggressive adopters of AI-driven drug discovery platforms, using computational tools to identify novel targets, predict molecular interactions, and optimize clinical trial designs. This AI-powered approach has compressed development timelines and reduced the cost of early-stage research, enabling companies like Innovent to build deep oncology pipelines that would have been prohibitively expensive to develop using traditional methods. The combination of AI-accelerated discovery and China’s large patient population — which provides access to diverse clinical trial cohorts, is a structural advantage that global pharmaceutical companies are increasingly eager to access through partnerships rather than compete against directly.
The Innovent-Pfizer deal also carries symbolic weight at a moment of heightened U.S.-China tensions. Unlike the semiconductor and AI hardware sectors, where U.S. export controls have sharply curtailed commercial cooperation, the pharmaceutical sector has remained a relatively open channel for collaboration. Both governments have strong incentives to maintain this openness: patients on both sides benefit from accelerated drug development, and the financial flows from licensing deals support innovation ecosystems in both countries. The deal’s scale, at $10.5 billion, it is one of the largest U.S.-China biotech partnerships on record, suggests that commercial logic continues to override geopolitical friction in sectors where the mutual benefits are sufficiently large.